Fulcrum Equity Partners

Fulcrum Equity Partners has spent nearly two decades backing high-growth B2B software and healthcare services companies from its Atlanta base. Founded in 2006, the firm has grown to manage approximately $1 billion in capital and has made over 60 investments across five funds. Their tagline says it all: "Go Further, Faster" — and they mean it literally. Unlike passive investors, Fulcrum deploys capital alongside hands-on operational support, taking board seats and actively working with founders to accelerate growth.

The firm's investment thesis is disciplined and narrow: they stick to what they know. B2B software companies with $2-15 million in annual recurring revenue metrics growing at least 40% year-over-year, and healthcare services companies with $1-15 million in EBITDA growing 20%+ annually. This specificity is a feature, not a limitation — founders who fit these criteria will find a firm that truly understands their space.

What sets Fulcrum apart is their operational mentality. Partners bring personal operating experience to bear on portfolio companies, whether that's hiring decisions, go-to-market strategy, or navigating a sale process. They invest $5-35 million of equity in both minority and majority positions, which means they're willing to take meaningful stakes and provide real leverage.

The firm has a demonstrated track record across market cycles. Their portfolio includes companies that have gone on to IPOs and acquisitions — Tricentis, Stax, and IPG are among the notable exits. More recently, they've backed companies like Canvs (AI insights for brands), FieldPulse (field services software), and MedScout (MedTech revenue acceleration). With five funds behind them, Fulcrum has the bandwidth and capital reserves to support portfolio companies through multiple financing rounds.

Fulcrum Equity Partners operates with a clear and tested philosophy: invest in sectors where the team has deep domain expertise, back founders with authentic industry knowledge, and provide more than money. Their website states it plainly — they invest capital and resources, and they stick to what they know.

The firm's criteria reflect hard-won lessons from 60+ investments. For B2B software companies, Fulcrum looks for $2-15 million in ARR benchmarks with demonstrable 40% year-over-year growth and strong net revenue retention. They prize companies where the founding team has direct experience in their target vertical — not just technical skills, but genuine domain fluency.

For healthcare services investments, the metrics shift to EBITDA ($1-15 million) with 20%+ annual growth, but the thesis remains consistent. Fulcrum gravitates toward companies addressing quality outcomes, cost reduction, multi-site expansion, and ancillary services. Post-acute care, addiction treatment centers, and management services organizations have all appeared in their portfolio.

Fulcrum typically leads or co-leads their investments. This isn't a scout-and-follow fund — they want board visibility, operational influence, and the ability to actively help founders navigate growth. For founders, this means more than a check; it means a partner who has likely seen your specific challenge before and can offer informed guidance.

The firm's investment committee evaluates candidates on market size, product differentiation, and team composition. Importantly, Fulcrum also weighs team chemistry — they want to work alongside founders who will listen, adapt, and build lasting companies rather than chasing the quickest exit.

Fulcrum's most recent Fund V is actively deploying capital into both B2B software and healthcare services. Their current portfolio reflects continued conviction in AI-powered business intelligence (Canvs), field service management software (FieldPulse), and healthcare IT platforms (MedScout, Hatch). These investments align with the firm's thesis of backing proven models in familiar verticals.

The firm has also backed companies like NavigatorCRE (commercial real estate intelligence), Virtuous (fundraising automation for nonprofits), and StudentBridge (higher education enrollment support) — all B2B software plays with clear domain focus and recurring revenue metrics models.

Healthcare services investments in Fund V include Pediatrics Plus (developmental preschool and therapy), Physician Services Group (post-acute care), Defining Wellness Centers (addiction treatment), and SurgNet Health Partners (ASC development and management). These represent the full continuum of post-acute and specialty healthcare services that Fulcrum has cultivated expertise in over multiple fund cycles.

Fulcrum's discipline around sector concentration means they often see the same patterns across their portfolio. When one portfolio company faces a specific challenge — say, hiring a VP of sales or navigating a regulatory change — Fulcrum can connect them with another founder who has solved the same problem. This peer network effect is a genuine value-add that most funds cannot replicate.

Fulcrum's portfolio spans industries and stages, but several names stand out for their trajectory and market position. Tricentis, which pioneered agile platform testing, remains active in Fulcrum's portfolio after multiple years of growth. Stax, an integrated payment platform, achieved significant scale before its exit. IPG, a medical implant solutions company, is another notable exit from earlier funds.

Kevel, which builds custom advertising platforms for publishers and marketplaces, represents Fulcrum's B2B software thesis executed well — strong recurring revenue metrics, clear product differentiation, and a team with deep MarTech expertise. The firm has backed other AdvertisingTech adjacencies as well.

DriverReach, a trucking tracking and compliance platform, is a recent exit that illustrates Fulcrum's willingness to back vertical SaaS plays in regulated industries. The trucking sector's compliance demands create natural friction that good software can eliminate — and DriverReach addressed exactly that.

On the healthcare side, Summit Spine & Joint Centers (interventional pain management) and Texas Endovascular (outpatient vein treatment) show Fulcrum's comfort with clinical services organizations that have multi-site expansion potential. These businesses trade at meaningful multiples when scaled correctly, and Fulcrum has the operational playbook to help founders get there.

Newer entrants like MedScout (MedTech revenue acceleration) and Canvs (AI-powered consumer insights) represent the firm's willingness to back companies at the intersection of software and emerging tech. These deals tend to command higher valuations but also offer the outsized returns that growth equity investors target.

Fulcrum evaluates candidates against specific quantitative thresholds before considering anything else. For B2B software, that means $2-15M in ARR benchmarks and 40%+ growth — not aspirational projections, but current metrics that demonstrate product-market fit is established. For healthcare services, $1-15M EBITDA with 20%+ growth serves the same function.

Beyond the numbers, Fulcrum digs into unit economics and net revenue retention. If your SaaS business is growing fast but hemorrhaging revenue from churn, that warrants explanation. Strong retention signals that customers find genuine value and that your land-and-expand potential is real.

The founding team matters enormously to Fulcrum. They want entrepreneurs who have lived in their target verticals — not dabbled, but worked. A former hospital administrator founding a healthcare services company, or a former ad tech executive building a publishing tools business, will get far more traction than a career investor entering a new sector.

Product differentiation needs to be defensible. Fulcrum asks: Do you have proprietary data, exclusive relationships, or technology that competitors cannot easily replicate? In healthcare services, multi-site expansion capability and ancillary service offerings create moats. In B2B software, switching costs and integration depth serve the same purpose.

Fulcrum also assesses capital efficiency. They prefer companies that have demonstrated an ability to grow without burning through enormous amounts of cash — a lesson many 2021-vintage companies learned the hard way. Your path to profitability or the next milestone should be credible and proximate, not contingent on perfect market conditions.

Fulcrum responds best to warm introductions from their existing portfolio founders, other growth equity investors they know well, or intermediaries (lawyers, bankers) who work with the firm regularly. Cold outreach is a lower-probability path, but not impossible — especially if you are squarely in their sector focus and hitting their numerical criteria.

If you do cold outreach, your deck should lead with revenue, growth, and retention data. Do not bury the metrics in a narrative — get to the numbers within the first three slides. Fulcrum's partners will scan for the ARR benchmarks figure, the growth rate, and the churn/retention profile before reading anything else.

The firm publishes their criteria directly on their website at fulcrumep.com, which tells you exactly what they look for. Studying that page before reaching out is basic hygiene — and demonstrating that you did your homework will improve your signal.

Once you secure a meeting, expect a direct conversation. Fulcrum's partners ask tough questions about assumptions, market sizing, and competitive positioning. They will push back on your projections. The founders who impress them come prepared with data to support their answers — and the intellectual honesty to acknowledge what they do not know.

Follow-through matters. Fulcrum typically takes 2-4 weeks from initial meeting to term sheet, though timing varies with deal complexity and partner bandwidth. Maintain communication without being a nuisance. Milestone updates — new logos signed, product launches, financing closes — are genuinely useful signals.

Growth equity investors like Fulcrum expect financial rigor. Even at the earlier end of their check range, they will scrutinize your model, your unit economics, and your assumptions about how capital will be deployed. If you cannot explain your CAC payback period, your cohort retention curves, or your path to profitability with precision, you will lose credibility quickly.

The stakes are higher with growth equity than seed-stage investing. Fulcrum is writing $5-35M checks, which means their return expectations are commensurately larger. A 2x on a $10M check is not a compelling outcome — founders need to understand what multiples are needed to attract this caliber of capital and build their businesses accordingly.

Working with a fractional CFO who understands growth equity expectations can meaningfully improve your fundraising odds. An experienced CFO can stress-test your model, surface weaknesses before investors do, and help you build the financial narrative that makes a compelling case. They also help you practice for the Q&A — the kinds of questions that trip up founders who have not stress-tested their assumptions.

For healthcare services companies specifically, EBITDA normalization is a common due diligence issue. Fulcrum will want to understand your EBITDA after adding back owner compensation, one-time items, and any non-recurring expenses. Getting your financial house in order before pitching — not during diligence — is a significant advantage.

Whether you are approaching Fulcrum Equity Partners or another growth equity firm with similar criteria, professional financial infrastructure sets you apart from the majority of founders who come in with incomplete models and under-prepared narratives. The firms that close growth rounds fastest are the ones where the financials speak for themselves.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and tips for securing funding. Whether you are looking for seed-stage investors or growth equity firms, you will find valuable insights in our VC firm guides.

Finding the right investor for your startup is crucial to your success. Take the time to research potential investors and understand their investment thesis before reaching out.

Our guides cover major venture capital firms as well as emerging managers that may be a better fit for your company's specific needs and stage.

For more information, visit Fulcrum Equity Partners at .